These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 33151508

  • 21. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
    Bonora BM, Avogaro A, Fadini GP.
    Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
    Stougaard EB, Kristensen PL, Kielgast U, Andersen HU, Hamid Y, Gæde PH, Søndergaard E, Dørflinger GH, Fjeldborg KK, Hansen KW, Thomsen HH, Al-Imar TMJ, Røder M, Sridhar VS, Cherney D, Rossing P, Persson F.
    Diab Vasc Dis Res; 2022 Jan; 19(5):14791641221130043. PubMed ID: 36262089
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
    Taverner S, Eng C, Watson R, George S, Edwards A, Williams DM, Stephens JW.
    Diabetes Metab Syndr; 2022 Dec; 16(12):102658. PubMed ID: 36371968
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study.
    Zhao Q, Tan Y, Wu Q, Xiao X, Wei X, Nian M, Yao J, Fan N, Wang R, Fan G.
    Expert Opin Drug Saf; 2024 Jan; 23(1):57-65. PubMed ID: 37947121
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [SGLT 2 inhibitors in Type 1 diabetes].
    Stougaard EB, Amadid H, Søndergaard E, Jørgensen ME, Persson F, Rossing P.
    Ugeskr Laeger; 2020 Aug 24; 182(35):. PubMed ID: 32829747
    [Abstract] [Full Text] [Related]

  • 38. Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors.
    Limenta M, Ho CSC, Poh JWW, Goh SY, Toh DSL.
    Clin Drug Investig; 2019 Jul 24; 39(7):683-690. PubMed ID: 31065934
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Inpatient case characteristics of SGLT2 inhibitor-associated diabetic ketoacidosis: a retrospective study.
    Yang Z, Zhang W, Chen H, Peng Q.
    Eur J Hosp Pharm; 2024 Jun 06. PubMed ID: 38844329
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.